GlassScriptPhysician profile
Michael Charles Margulies
NPI 1992793731
$446.17
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $71.29 · 2021: $22.21.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $118.42 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $94.35 | 2019 | |
| Genentech USA, INC. | $61.94 | 2019-2020 | |
| Pfizer INC. | $38.24 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.41 | 2019-2021 | |
| Lilly USA, LLC | $35.14 | 2019 | |
| Promius Pharma LLC | $19.48 | 2019 | |
| Genzyme Corporation | $17.92 | 2019 | |
| Janssen Biotech, INC. | $13.36 | 2020 | |
| Sun Pharmaceutical Industries INC. | $11.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Margulies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.